Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications
about
Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathwayMutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction.Adenosine A(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's DiseaseMembrane cholesterol access into a G-protein-coupled receptor.Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimersFluorescent protein complementation assays: new tools to study G protein-coupled receptor oligomerization and GPCR-mediated signaling.Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's diseaseNew treatments for the motor symptoms of Parkinson's disease.Pathophysiological roles for purines: adenosine, caffeine and urate.Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated ratsAdenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum.The effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2A(2A) Receptor Antagonism and Dyskinesia in Parkinson's DiseaseChemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.Adenosine A2A Receptor Blockade Prevents Rotenone-Induced Motor Impairment in a Rat Model of Parkinsonism.Superior working memory and behavioural habituation but diminished psychomotor coordination in mice lacking the ecto-5'-nucleotidase (CD73) gene.Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's diseaseTriggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotectionNovel investigational adenosine A2A receptor antagonists for Parkinson's disease.Neurotransmission in Parkinson's disease: beyond dopamine.Tuning and fine-tuning of synapses with adenosine.Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson's Mice.The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects.Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.Perspectives of purinergic signaling in stem cell differentiation and tissue regeneration.New synaptic and molecular targets for neuroprotection in Parkinson's disease.Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor fieldLevodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsPharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism.Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia.Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy.Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
P2860
Q24646576-19CBC9BD-2245-48F1-A0F5-5C2B375F555DQ29347530-5701E7B9-1ACA-45A3-BE69-A92965BE5ECBQ30472044-A4669F46-D777-42EC-909C-D41D8D304FBEQ30839707-7283E550-1578-42C9-AE02-FB8A44FFF762Q33714838-D7FB72BF-3659-49C4-94A3-E27D4F3404C5Q34345068-40BCFB70-3528-42CC-917D-3F0F4A091AFCQ34419833-90E0490D-AACB-4431-A50A-EC776F364345Q34443682-87F92E9B-4567-4E73-B86A-1F8DDF201268Q35008049-00821830-46AF-4028-B95B-BDABE4504D5FQ35607243-984694E7-9CC4-4A31-8703-41A94A393E71Q35614156-EC82E515-1892-457E-BC2F-1B49C93FDD2BQ35635814-E8241F43-5603-412B-860D-838ECBE23383Q35917127-9D511F8F-A926-4EF5-85D8-9FC9BCE15004Q36010835-CCEF8B62-0278-4353-8239-26D3140C91C3Q36057652-0B4CB6A9-7802-4563-AE00-3D5A1CC17231Q36250876-B99ED59D-D713-4B37-A8E5-95424831199FQ36627429-6E599622-4F15-4A4E-8163-9EC7C52317CDQ36821543-82024B78-ADE9-4EB6-9B31-BC2E2DE8F358Q37358676-83E399BC-31DE-479F-9B5E-31B93A505C99Q37512421-151B7C37-1C55-455B-AB07-D4799FD66643Q37627259-448DC92F-A1A1-4E00-9738-55363CB89E7AQ37668684-B4A4D0D6-8799-4F1F-B6C1-55A2EE74082BQ37700201-9B69D10A-6755-4DED-94C1-9F88CD2DFC73Q37712460-93A1F58C-BA2C-46C4-B26E-0CD56657AD23Q37852727-CF8F8D4F-6173-44C4-86CB-D770964F5591Q37902895-D03861E1-6041-47F8-8FCA-1422B23699A4Q37924629-683326E3-A1EB-4064-9A27-B4D75F5CCB0AQ37963718-4E09DD0D-D8D3-43D3-AD64-72C4C441757BQ37964983-349CAF06-DFAD-4DE8-B61C-CA16AD3D99A9Q38038559-06D89E06-1357-4908-BD55-3FA9E626B56EQ38150698-A77A695F-5ABB-4738-B053-D1C6AB657473Q38156760-1B1BD3B9-3786-426B-B435-D36C1166B149Q38262418-B2399AD2-14D3-4986-9408-978D05FB2A72Q38660240-4BB7E637-D906-4325-956B-CD94537CD54CQ39432789-F25EDD4E-7646-4F54-929F-170010DBD58EQ41584434-A1AEB275-0650-43EA-92A6-1108966974BCQ41899842-3C96F1F5-78AD-4E8E-A8C8-5E734709DF6AQ42126269-21B1F99B-3624-4C6D-89EB-B85B68A529C2Q47627884-5D2849CB-893C-4D30-9F51-660247AB3D8BQ48357495-D50D4268-1A43-471F-A2AD-84A191120542
P2860
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Role of adenosine A2A receptor ...... PA-induced motor complications
@ast
Role of adenosine A2A receptor ...... PA-induced motor complications
@en
Role of adenosine A2A receptor ...... PA-induced motor complications
@nl
type
label
Role of adenosine A2A receptor ...... PA-induced motor complications
@ast
Role of adenosine A2A receptor ...... PA-induced motor complications
@en
Role of adenosine A2A receptor ...... PA-induced motor complications
@nl
prefLabel
Role of adenosine A2A receptor ...... PA-induced motor complications
@ast
Role of adenosine A2A receptor ...... PA-induced motor complications
@en
Role of adenosine A2A receptor ...... PA-induced motor complications
@nl
P2093
P50
P1476
Role of adenosine A2A receptor ...... PA-induced motor complications
@en
P2093
Danqing Xiao
Frederic Calon
Micaela Morelli
P304
P356
10.1016/J.PNEUROBIO.2007.07.001
P407
P577
2007-12-01T00:00:00Z